GLP-1, a glucagon-like peptide-1 secreted in the small intestine, promotes insulin production in the pancreas, thereby ...

Samsung Bioepis’ ustekinumab biosimilar receives Japanese marketing approval: Incheon, Korea Wednesday, December 24, 2025, 15:00 Hrs [IST] Samsung Bioepis Co., Ltd., a biopharma ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...

Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...

On Monday evening, the Food and Drug Administration approved Novo Nordisk’s high-dose oral formulation of semaglutide for ...

Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct ...

Genentech, a subsidiary of the Roche Group, has received the US FDA accelerated approval for Lunsumio VELO SC formulation to ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...